-
Innovation Ranking
NewInnovation Ranking – U.S. Bancorp
U.S. Bancorp (USB) is a diversified financial services company that offers retail and commercial banking, private banking, and wealth management solutions through its subsidiaries. Its portfolio of products and services comprises savings and checking accounts, certificate of deposits, consumer and business loans, personal and business lines of credit, mortgages, insurance, savings and investment products, brokerage and fund services, credit and debit cards, asset and wealth management, and financial planning solutions. The company also provides leasing, international banking, payment services, private...
-
Innovation Ranking
NewInnovation Ranking – U.S. Silica Holdings Inc
U.S. Silica Holdings Inc (U.S. Silica) is the domestic producer of commercial silica. The company produces industrial minerals, including sand proppants, ground silica, whole grain silica, fine ground silica, diatomaceous earth, and aplite clay. It also offers oil and gas proppants, testing silica, fillers and extenders, recreational silica, and FLORISIL adsorbent. U.S. Silica products find its applications in plastics, polishes, paints, textile fiberglass, rubber, cleansers, glazes, and precision castings. It also provides logistics services. U.S. Silica is headquartered in Katy,...
-
Product Insights
U.S. Department of Energy’s Brookhaven National Laboratory
U.S. Department of Energy’s Brookhaven National Laboratory is a solar PV project located in New York, United States. The project is owned and developed by BP Solar International Inc; Metlife Capital Limited Partnership. The project came online in 2011. Empower your strategies with our U.S. Department of Energy’s Brookhaven National Laboratory report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Company Insights
Innovation and Patenting activity of U.S. Bancorp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Bancorp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of U.S. Concrete Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Concrete Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of U.S. Silica Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Silica Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Breast Cancer Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine derivative,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Refractory Multiple Myeloma Drug Details: Enzalutamide (Xtandi) is...